HIKAL

- Mr. Jai Hiremath ceased to be Executive Chairman effective October 01, 2026, and was conferred the honorary position of Chairman Emeritus for 5 years. - Mrs. Sugandha Hiremath resigned as Non-Executive Director effective September 30, 2026, due to personal commitments. - Mr. Anish Swadi was appointed as CEO - Animal Health and Specialty Ingredients effective October 01, 2026.

- Hikal Limited received an independent ESG rating of “Crisil ESG 65” for FY 2025-26 from Crisil ESG Ratings & Analytics Limited. - The rating was independently prepared based on public data without direct engagement by the company. - The company outperformed peers in renewable energy share, waste recycling, employee safety, board diversity, and stakeholder grievance management.

- Trading window for Designated Persons and their immediate relatives will close from October 01, 2026. - Remains closed until 48 hours post declaration of financial results for the quarter and half-year ending September 30, 2026.

- Hikal shareholders approved Sameer Hiremath's appointment as Chairman & MD at the 38th AGM. - FY2025-26 financials and a Rs. 0.40 final dividend were approved. - Commercial production of Personal Care products began at a new Gujarat facility. - Hikal received the EcoVadis Gold Medal for sustainability.

- Hikal Limited commenced commercial production at its new cGMP Panoli facility in Gujarat for personal care products. - This marks the company's formal entry into commercial-scale Personal Care manufacturing, focusing on skin care and second-generation UV filters.

- Investor Meeting Schedule - Date: September 04, 2026 - Time: 12:00 P.M. (IST) onwards - Type: In-Person Group Meeting at Pune R&T centre to interact with Company officials.

- Hikal Limited announced its 38th Annual General Meeting (AGM) will be held on September 23, 2026, at 11:30 a.m. (IST) via Video Conferencing/OAVM. - The web-link for accessing the Annual Report for the financial year 2025-26 has been provided. - Members are reminded to update KYC details and dematerialize physical securities as per SEBI regulations.

- Hikal Ltd. filed its Annual Report for FY2025-26 and Notice of 38th AGM. - FY2025-26 financials: Revenue ₹17,126 Million, EBITDA ₹2,328 Million, EBITDA Margin 13.6%. - Company notes improved execution and recovering demand, positioning for future growth and maintained 'A' credit rating by ICRA.

New Filing detected. See link for details.

- Hikal Ltd. will hold its 38th Annual General Meeting (AGM) on September 23, 2026, at 11:30 a.m. (IST) via Video Conferencing/Other Audio Visual Means (OAVM). - The record date for determining eligible members for the payment of Final Dividend for FY 2025-26 is September 04, 2026. - The Final Dividend, if declared at the AGM, will be paid on or before October 23, 2026.

- The 38th Annual General Meeting (AGM) of Hikal Limited is scheduled for Wednesday, September 23, 2026, at 11:30 a.m. (IST) via Video Conferencing/OAVM. - The Record Date for determining eligibility for the Final Dividend for the Financial Year 2025-26 has been fixed as Friday, September 04, 2026. - The Final Dividend, if declared at the AGM, will be paid to eligible shareholders on or before October 23, 2026.

- Hikal's Board approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director for a period of 5 years, commencing October 01, 2026, to September 30, 2031, subject to shareholder approval.

- Q1 FY27 reported consolidated revenue of Rs 403 crores with an EBITDA margin of 9.2%. - The company reported a Net Loss (PAT) of Rs (-7) crores for Q1 FY27. - Pharmaceutical business revenue was Rs 233 crores with EBIT of Rs 8 crores (3.2% margin); Crop Protection business reported EBIT of Rs (-6) crores due to margin pressure from raw material costs and competition. - Net debt reduced from Rs. 815 crores in FY24 to Rs. 685 crores by end of FY26, with a debt-to-equity ratio of 0.53. - Management expects FY27 full-year revenue growth of 14%-16% and EBITDA growth of 25%-30%. - U.S. FDA remediation program is on track, with re-inspection expected towards the end of FY27, anticipating accelerated growth and improved EBITDA margins in FY28 and beyond. - Animal Health business is projected to reach Rs. 400 crores+ by FY30 with over 20% EBITDA margins. - New Personal Care business is expected to generate Rs. 200 crores in revenue within three years with over 20% EBITDA margins. - Crop Protection business is expected to show very marginal growth (mid to high single digit) in FY27 due to continued pricing pressure and elevated raw material costs.

- Audio recording of the earnings group conference call for the quarter ended June 30, 2026, held on August 06, 2026, at 05:00 PM (IST) is available. - The recording can be accessed at hikal.com/uploads/documents/10045984.mp3.

- Consolidated Revenue ₹403Cr vs ₹380Cr (▲6.05% YoY) - EBITDA ₹37Cr vs ₹25Cr (▲48% YoY) - PAT ₹-7Cr vs ₹-22Cr (Loss reduced YoY) - EBITDA Margin 9.2% vs 6.6% (▲260bps)

- Consolidated Revenue ₹403 Cr vs ₹380 Cr (▲5.9% YoY) - EBITDA ₹37 Cr vs ₹25 Cr (▲47.4% YoY) - PAT (Loss) ₹7 Cr vs (Loss) ₹22 Cr (Reduced loss YoY) - EBITDA Margin 9.2% vs 6.6% (▲259bps)

- Consolidated Revenue ₹4,028 Million vs ₹3,804 Million (▲5.9% YoY) - EBITDA ₹370 Million vs ₹251 Million (▲47.4% YoY) - PAT ₹(74) Million vs ₹(224) Million (Loss reduced by 67.0% YoY) - EBITDA Margin 9.2% vs 6.6% (▲260bps)

- Concall Schedule - Concall Date: Thursday, August 06, 2026 - Concall Time: 05:00 PM (IST)

- Hikal Limited has been awarded the EcoVadis Gold Medal for Sustainability Excellence. - The company is placed among the top 5% of over 175,000 companies assessed globally by EcoVadis. - Hikal achieved an overall score of 84/100 and a 97th percentile ranking. - The award is valid through July 2027.

- Hikal Limited announced the voting results for the appointment of Mr. Sandip Parikh as an Independent Director via postal ballot (e-voting conducted from June 05, 2026, to July 04, 2026). - The special resolution was passed with requisite majority. - 99.9865% of the valid votes cast were in favour of the appointment.

- The trading window for Designated Persons and their immediate relatives is closed from July 01, 2026. - It will reopen 48 hours after the declaration of financial results for the quarter ending June 30, 2026.